Parsons Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Parsons Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$389K	Hold	21,645	–	–	0.02%	412
2026 Q1	$301K	Hold	21,645	–	–	0.01%	416
2025 Q4	$261K	Hold	21,645	–	–	0.01%	420
2025 Q3	$294K	Hold	21,645	–	–	0.02%	388
2025 Q2	$139K	Hold	21,645	–	–	0.01%	433
2025 Q1	$76.6K	Hold	21,645	–	–	﹤0.01%	429
2024 Q4	$81.8K	Sell	21,645 -300	-1%	-$1.41K	﹤0.01%	436
2024 Q3	$71.1K	Hold	21,945	–	–	﹤0.01%	438
2024 Q2	$41.7K	Hold	21,945	–	–	﹤0.01%	435
2024 Q1	$62.3K	Hold	21,945	–	–	﹤0.01%	433
2023 Q4	$323K	Hold	21,945	–	–	0.02%	363
2023 Q3	$402K	Hold	21,945	–	–	0.03%	318
2023 Q2	$473K	Hold	21,945	–	–	0.04%	303
2023 Q1	$644K	Sell	21,945 -5,200	-19%	-$181K	0.05%	265
2022 Q4	$1M	Buy	27,145 +10,280	+61%	+$365K	0.08%	202
2022 Q3	$475K	Buy	+16,865	New	+$421K	0.04%	279

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Parsons Capital Management's AMLX Position: Q2 2026 in Review

Parsons Capital Management held its Amylyx Pharmaceuticals (AMLX) position steady in Q2 2026 at 21,645 shares worth $389K. The position accounts for 0.02% of the portfolio, ranked #412.

Parsons Capital Management first reported a position in AMLX in Q3 2022 and has held it in 16 quarters since. The position peaked at $1M in Q4 2022. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

Parsons Capital Management held 21,645 shares of Amylyx Pharmaceuticals worth $389K as of Q2 2026.
Parsons Capital Management left its Amylyx Pharmaceuticals share count unchanged in Q2 2026.
Amylyx Pharmaceuticals made up 0.02% of Parsons Capital Management's portfolio in Q2 2026, its #412 holding.
Parsons Capital Management first reported a position in Amylyx Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
Parsons Capital Management's Amylyx Pharmaceuticals position peaked at $1M in Q4 2022.
206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Parsons Capital Management's 13F filing for Q2 2026, filed 24 Jul 2026.